178 related articles for article (PubMed ID: 35906386)
1. SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm.
Zhang TJ; Xu ZJ; Wen XM; Gu Y; Ma JC; Yuan Q; Lin J; Zhou JD; Qian J
Leukemia; 2022 Oct; 36(10):2488-2498. PubMed ID: 35906386
[TBL] [Abstract][Full Text] [Related]
2. SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia.
Wu DL; Wang Y; Zhang TJ; Chu MQ; Xu ZJ; Yuan Q; Ma JC; Lin J; Qian J; Zhou JD
Eur J Med Res; 2022 Nov; 27(1):259. PubMed ID: 36411451
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes.
Zhou JD; Zhang TJ; Xu ZJ; Deng ZQ; Gu Y; Ma JC; Wen XM; Leng JY; Lin J; Chen SN; Qian J
Cell Death Dis; 2020 Nov; 11(11):997. PubMed ID: 33219204
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
[TBL] [Abstract][Full Text] [Related]
6. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
8. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract][Full Text] [Related]
9. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
Yan-Fang T; Jian N; Jun L; Na W; Pei-Fang X; Wen-Li Z; Dong W; Li P; Jian W; Xing F; Jian P
BMC Med Genet; 2013 Jul; 14():74. PubMed ID: 23870168
[TBL] [Abstract][Full Text] [Related]
10. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L; Hatzimichael E; Dasoula A; Dranitsaris G; Tsiara S; Syrrou M; Georgiou I; Bourantas KL
Leuk Res; 2010 Feb; 34(2):148-53. PubMed ID: 19595458
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
13. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
14. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of prognosis-related DLX5 methylation as an epigenetic driver in myeloid neoplasms.
Zhang TJ; Xu ZJ; Gu Y; Wen XM; Ma JC; Zhang W; Deng ZQ; Leng JY; Qian J; Lin J; Zhou JD
Clin Transl Med; 2020 Jun; 10(2):e29. PubMed ID: 32508046
[TBL] [Abstract][Full Text] [Related]
16. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.
Zhou JD; Lin J; Zhang TJ; Ma JC; Yang L; Wen XM; Guo H; Yang J; Deng ZQ; Qian J
Cancer Med; 2017 Jan; 6(1):267-274. PubMed ID: 27891827
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of SRY-box containing gene family member
Zhou JD; Wang YX; Zhang TJ; Li XX; Gu Y; Zhang W; Ma JC; Lin J; Qian J
Clin Epigenetics; 2018; 10():92. PubMed ID: 30002740
[TBL] [Abstract][Full Text] [Related]
18. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.
Kim GE; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Virchows Arch; 2011 Oct; 459(4):383-90. PubMed ID: 21894562
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
[TBL] [Abstract][Full Text] [Related]
20. Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome.
Wang H; Zhang TT; Jin S; Liu H; Zhang X; Ruan CG; Wu DP; Han Y; Wang XQ
Clin Epigenetics; 2017; 9():91. PubMed ID: 28861128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
